119 related articles for article (PubMed ID: 579164)
1. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics.
Bleyer AW
Cancer Treat Rep; 1977 Nov; 61(8):1419-25. PubMed ID: 579164
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
Bleyer WA; Dedrick RL
Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal methotrexate-induced neurotoxicities.
Nelson RW; Frank JT
Am J Hosp Pharm; 1981 Jan; 38(1):65-8. PubMed ID: 7011005
[TBL] [Abstract][Full Text] [Related]
6. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic model for predicting the concentration of methotrexate in plasma subsequent to intrathecal injection.
Ramu A; Fusner JE
Isr J Med Sci; 1979 Jun; 15(6):494-9. PubMed ID: 582316
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate. II. Use in pediatric chemotherapy.
Lippens RJ
Am J Pediatr Hematol Oncol; 1984; 6(4):397-413. PubMed ID: 6398630
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
Vezmar S; Schüsseler P; Becker A; Bode U; Jaehde U
Pediatr Blood Cancer; 2009 Jan; 52(1):26-32. PubMed ID: 19006245
[TBL] [Abstract][Full Text] [Related]
10. [Prophylactic CNS-leukemia therapy with cyclic intrathecal methotrexate and hydrocortisone injection (author's transl)].
Taguchi N; Koide R; Tsunematsu Y; Sasaki M; Kinugawa N; Takao A
Rinsho Ketsueki; 1979 Jun; 20(6):608-15. PubMed ID: 582457
[No Abstract] [Full Text] [Related]
11. Intrathecal methotrexate versus central nervous system leukemia.
Bleyer WA
Cancer Drug Deliv; 1984; 1(2):157-67. PubMed ID: 6399986
[TBL] [Abstract][Full Text] [Related]
12. [Effects of prophylactic treatment of central nervous system leukemia in children. Analysis of CNS prophylactic treatment with cyclic high dose multichemotherapy, craniospinal irradiation, and high dose infusion of MTX].
Abe Y; Asakura A; Endo N
Gan To Kagaku Ryoho; 1982 May; 9(5):855-65. PubMed ID: 6964040
[TBL] [Abstract][Full Text] [Related]
13. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study.
Adamson PC; Balis FM; Arndt CA; Holcenberg JS; Narang PK; Murphy RF; Gillespie AJ; Poplack DG
Cancer Res; 1991 Nov; 51(22):6079-83. PubMed ID: 1933871
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.
Amadori S; Tribalto M; Pacilli L; De Laurentis C; Papa G; Mandelli F
Cancer Treat Rep; 1980; 64(8-9):939-42. PubMed ID: 6934851
[TBL] [Abstract][Full Text] [Related]
17. [Effects of a massive dosage of methotrexate and leucovorin rescue therapy on acute leukemia and malignant lymphoma].
Gan To Kagaku Ryoho; 1982 Mar; 9(3):421-32. PubMed ID: 6764106
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
Fujimoto T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
Shapiro WR; Young DF; Mehta BM
N Engl J Med; 1975 Jul; 293(4):161-6. PubMed ID: 806016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
